Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and design.
Barreto J, Martins M, Pascoa M, Medorima STK, Bonilha I, Jesus DC, Carbonara CEM, Quadros KRS, Assato B, Campos-Staffico AM, Júnior GG, Nadruz W, de Oliveira RB, Sposito AC.
Barreto J, et al. Among authors: de oliveira rb.
Expert Opin Drug Saf. 2024 Oct 13:1-7. doi: 10.1080/14740338.2024.2412228. Online ahead of print.
Expert Opin Drug Saf. 2024.
PMID: 39377184